The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...

Any recent changes to analyst estimates for Pfizer should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) ...

Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 ...